🚀 VC round data is live in beta, check it out!
Santen Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Santen Pharmaceutical and similar public comparables like Virbac, Structure Therapeutics, Kanghong Pharmaceutical, Brightgene Bio-medical and more.
Santen Pharmaceutical Overview
About Santen Pharmaceutical
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
Founded
1890
HQ
Employees
3.8K
Website
Sectors
Financials (LTM)
EV
$3B
Santen Pharmaceutical Financials
Santen Pharmaceutical reported last 12-month revenue of $2B and EBITDA of $405M.
In the same LTM period, Santen Pharmaceutical generated $1B in gross profit, $405M in EBITDA, and $206M in net income.
Revenue (LTM)
Santen Pharmaceutical P&L
In the most recent fiscal year, Santen Pharmaceutical reported revenue of $2B and EBITDA of $440M.
Santen Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 52% | XXX | XXX | XXX |
| EBITDA | $405M | XXX | $440M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $206M | XXX | $248M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 12% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Santen Pharmaceutical Stock Performance
Santen Pharmaceutical has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
Santen Pharmaceutical's stock price is $11.13.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | -0.8% | XXX | XXX | XXX | $0.77 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSanten Pharmaceutical Valuation Multiples
Santen Pharmaceutical trades at 1.7x EV/Revenue multiple, and 7.8x EV/EBITDA.
EV / Revenue (LTM)
Santen Pharmaceutical Financial Valuation Multiples
As of April 18, 2026, Santen Pharmaceutical has market cap of $4B and EV of $3B.
Equity research analysts estimate Santen Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Santen Pharmaceutical has a P/E ratio of 17.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 7.8x | XXX | 7.2x | XXX | XXX | XXX |
| EV/EBIT | 10.9x | XXX | 9.9x | XXX | XXX | XXX |
| EV/Gross Profit | 3.0x | XXX | 2.9x | XXX | XXX | XXX |
| P/E | 17.4x | XXX | 14.5x | XXX | XXX | XXX |
| EV/FCF | 11.1x | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Santen Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Santen Pharmaceutical Margins & Growth Rates
Santen Pharmaceutical's revenue in the last 12 month grew by 2%.
Santen Pharmaceutical's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Santen Pharmaceutical's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Santen Pharmaceutical's rule of X is 25% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Santen Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | (10%) | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | (8%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 27% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 38% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Santen Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Santen Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Virbac | XXX | XXX | XXX | XXX | XXX | XXX |
| Structure Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kanghong Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Brightgene Bio-medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Aspen Pharmacare | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Santen Pharmaceutical M&A Activity
Santen Pharmaceutical acquired XXX companies to date.
Last acquisition by Santen Pharmaceutical was on XXXXXXXX, XXXXX. Santen Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Santen Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSanten Pharmaceutical Investment Activity
Santen Pharmaceutical invested in XXX companies to date.
Santen Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Santen Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Santen Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Santen Pharmaceutical
| When was Santen Pharmaceutical founded? | Santen Pharmaceutical was founded in 1890. |
| Where is Santen Pharmaceutical headquartered? | Santen Pharmaceutical is headquartered in Japan. |
| How many employees does Santen Pharmaceutical have? | As of today, Santen Pharmaceutical has over 3K employees. |
| Who is the CEO of Santen Pharmaceutical? | Santen Pharmaceutical's CEO is Tsuyoshi Ito. |
| Is Santen Pharmaceutical publicly listed? | Yes, Santen Pharmaceutical is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Santen Pharmaceutical? | Santen Pharmaceutical trades under 4536 ticker. |
| When did Santen Pharmaceutical go public? | Santen Pharmaceutical went public in 1964. |
| Who are competitors of Santen Pharmaceutical? | Santen Pharmaceutical main competitors are Virbac, Structure Therapeutics, Kanghong Pharmaceutical, Brightgene Bio-medical. |
| What is the current market cap of Santen Pharmaceutical? | Santen Pharmaceutical's current market cap is $4B. |
| What is the current revenue of Santen Pharmaceutical? | Santen Pharmaceutical's last 12 months revenue is $2B. |
| What is the current revenue growth of Santen Pharmaceutical? | Santen Pharmaceutical revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Santen Pharmaceutical? | Current revenue multiple of Santen Pharmaceutical is 1.7x. |
| Is Santen Pharmaceutical profitable? | Yes, Santen Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Santen Pharmaceutical? | Santen Pharmaceutical's last 12 months EBITDA is $405M. |
| What is Santen Pharmaceutical's EBITDA margin? | Santen Pharmaceutical's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Santen Pharmaceutical? | Current EBITDA multiple of Santen Pharmaceutical is 7.8x. |
| What is the current FCF of Santen Pharmaceutical? | Santen Pharmaceutical's last 12 months FCF is $286M. |
| What is Santen Pharmaceutical's FCF margin? | Santen Pharmaceutical's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Santen Pharmaceutical? | Current FCF multiple of Santen Pharmaceutical is 11.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.